CRP and myocardial infarction: Given that the majority of benefits from Canakinumab is in patients with documented inflammation and high risk of cardiovascular events, some experts suggest that canakinumab may be considered for patients with prior myocardial infarction, high-sensitivity C-reactive protein levels of 2 mg/L or greater, and low-density lipoprotein cholesterol levels below 70 mg/dL, who are at high risk of recurrent events despite optimal medical therapy.